2/ 🧬 Se reconocen sus aportaciones de altísimo nivel en Biología Molecular, con avances singulares en la comprensión de la integridad del genoma, que han tenido un impacto directo en la ciencia y la sociedad, incluyendo la puesta en marcha de plataformas tecnológicas e institutos de investigación.
2/ 📌 Consejo: si el foco es la enfermedad, preséntalo en su área correspondiente, pero si el foco es la tecnología, preséntalo en el área de tecnologías facilitadoras.
📅 Apúntate a la sesión informativa de este miércoles 08/10
1/ 🚀Advanced therapies hold immense promise—yet turning breakthroughs into real treatments requires more than innovation.
At #HealthResearchMeeting, Silvia Martín-Lluesma (@vhio.bsky.social) explored the long road from lab to patient, and the hurdles to make therapies accessible for all.👇
5/🤖Another key player is AI in healthcare, but happens when hype meets reality?
The main challenge isn’t better algorithms, but the physical and energy limits of supporting infrastructure. It is adoption, integration, and smart implementation that will define its real impact.🏛
3/ Global competition for talent is intensifying.📈
Migration policies are polarizing, pushing researchers away from some countries, while intensifying competition for talent in others that are prioritizing skilled scientists attraction.
2/Funding is shifting fast. How is this happening?💸
Federal support is shrinking in some regions, while universities turn to industry, while tariffs, geopolitical tensions, and evolution in the pharmaceutical industry are reshaping where and how R&D happens.
1/ 🚀Advanced therapies hold immense promise—yet turning breakthroughs into real treatments requires more than innovation.
At #HealthResearchMeeting, Silvia Martín-Lluesma (@vhio.bsky.social) explored the long road from lab to patient, and the hurdles to make therapies accessible for all.👇
6/What can do researchers to overcome the critical —but often overlooked— keystones?
1️⃣Seek expert ATMPs organizations early, 2️⃣plan for good manufacturing practices requirements, 3️⃣adapt clinical trial design to your target, 4️⃣secure sustained funding—preclinical to clinical.
